CRISPR gene editing moved into humans in 2017 | Science News

ADVERTISEMENT

MISSION CRITICAL

Support credible science journalism.

Subscribe to Science News today.


Year in Review

CRISPR gene editing moved into new territory in 2017

Debates about when and how to use the tool in humans take on new urgency

By
8:30am, December 13, 2017
single cell embryo

HUMAN DEBUT  In the last year, research teams have announced CRISPR gene editing in viable human embryos (single-cell embryo shown).

Sponsor Message

Scientists reported selectively altering genes in viable human embryos for the first time this year. For nearly five years, researchers have been wielding the molecular scissors known as CRISPR/Cas9 to make precise changes in animals’ DNA. But its use in human embryos has more profound implications, researchers and ethicists say.

“We can now literally change our own species,” says Mildred Solomon, a bioethicist and president of the Hastings Center, a bioethics research institute in Garrison, N.Y.

CRISPR/Cas9 is a bacterial immune system (SN: 4/15/17, p. 22) turned into a powerful gene-editing tool. First described in 2012, the editor consists of a DNA-cutting enzyme called Cas9 and a short piece of RNA that guides the enzyme to a specific spot that scientists want to edit. Once the editing machinery reaches its destination, Cas9 cleaves the DNA. Cells can repair the break by gluing the cut ends back together, or by pasting in another piece of DNA. Scientists have developed variations of the editor that make other changes to DNA without cutting, including one version described in October that performs a previously impossible conversion of one DNA base into another.

Whether scientists should use CRISPR/Cas9’s power to create gene-edited babies is a matter of heated debate. Until March, the battles were mostly academic because previous attempts to edit human embryos were done in embryos that would never develop into a baby (SN Online: 4/8/16; SN Online: 4/23/15). But in March, Lichun Tang of China’s Beijing Proteome Research Center and colleagues reported using CRISPR/Cas9 to correct disease-causing mutations in a small number of viable human embryos. Other groups posted separate reports of CRISPR/Cas9 repair in viable human embryos in August and October.

Rather than edit out problems, a different group led by developmental biologist Kathy Niakan of the Francis Crick Institute in London snipped DNA with CRISPR/Cas9 to intentionally create mutations in human embryos for the first time. Those embryos were used to study the role of a gene important in development (SN: 10/14/17, p. 8).

Together, the studies illustrate that the gene-editing technology can make a variety of changes in human DNA that would last a lifetime and stretch across generations. It’s the relative ease and permanence that have many people worried that CRISPR/Cas9 could lead to new classes of genetically enhanced people and discrimination against others born with uncorrected genetic diseases. Taken to extremes, that discrimination could extend to people whose parents chose not to (or didn’t have the means to) genetically alter their children’s athletic power, intellectual ability or other characteristics.

In February, a panel of ethicists and other experts convened by the U.S. National Academies of Sciences, Engineering and Medicine warned against using CRISPR to enhance health or other traits. But the panel said using human gene editing to correct diseases, in certain circumstances, could be permissible (SN: 3/18/17, p. 7).

No babies have been born with changes made by CRISPR/Cas9 or any other gene-editing technology. But it could be only a matter of time. “I would not be surprised if there were a CRISPR-modified baby somewhere in the world in the next couple of years,” said CRISPR pioneer Jennifer Doudna of the University of California, Berkeley on October 26 in San Francisco at the World Conference of Science Journalists. Doudna said she does not support using CRISPR/Cas9 to make gene-edited babies.

Researchers, including Shoukhrat Mitalipov of Oregon Health & Science University in Portland, say improving the technology to make it safer and more effective is important for tackling genetic diseases at their source — the faulty genes. A study from Mitalipov and colleagues, published in Nature in August, suggests that making so-called “designer babies” could be harder than people expect (SN: 9/2/17, p. 6). Instead of using a piece of DNA that the researchers injected to repair cuts made by CRISPR/Cas9, human embryos used their own DNA from another chromosome as a repair template. That could make adding outside genes to enhance traits more difficult, but fixing some disease-causing mutations would potentially be easier, Mitalipov says. If one healthy copy of the gene exists, the cell, theoretically, would use it as a repair template.

Genetic rewrite

Base editors fuse enzymes that can alter the chemical structure of DNA bases to a “dead” version of CRISPR/Cas9 that doesn’t cut DNA. The first base editors developed in 2016 use cytidine deaminase to change C-G base pairs to T-A pairs (top). A new base editor (bottom) uses DNA adenine deaminase to make the opposite change, transforming A-T base pairs to G-C pairs.

The study soon came under criticism from other researchers. “The evidence for fixing is not there,” says Dieter Egli, a developmental biologist at Columbia University. Mitalipov and colleagues have not presented enough data to support their interpretation, he says. Egli and colleagues posted their criticism online August 28 at bioRxiv.org. “The conclusion that the correction occurred is, at best, premature,” Egli says. “At worst, it might be false.”

Mitalipov and Oregon colleague Paula Amato say they have submitted more evidence to support their claim to Nature and hope to publish the data soon. The finding needs to be replicated by other groups, Amato says, but “at the moment, we stand by our conclusions.”

It may also be possible to fix genetic mutations without any cutting. By dulling Cas9’s blades, researchers led by David Liu of Harvard University have developed “base editors.” The enzyme can grasp DNA but not slice through it. The researchers attached other enzymes that chemically change one DNA base into another. DNA bases are the information-carrying part of the DNA molecule and are often represented by A, C, T and G. In 2016, Liu described a base editor that transforms a C into a T.

Then a team of Chinese researchers used that base editor to correct a mutation in human embryos that causes the blood disorder beta-thalassemia, reported September 23 in Protein & Cell (SN: 11/25/17, p. 7). In October, Liu and colleagues reported that they’d made another base editor that can do a previously impossible trick: convert an A into a G. The two base editors together may allow researchers to repair most of the single base mutations responsible for causing human diseases, such as sickle-cell anemia, muscular dystrophy and cystic fibrosis.

But before any type of human embryo editing can be used in the clinic, it must be as safe and effective as existing embryo screening methods. Today, doctors working with embryos created through in vitro fertilization can extract a few cells for genetic testing in a process called preimplantation genetic diagnosis, or PGD. Embryos that don’t have mutations can be transferred to a woman’s uterus to establish a pregnancy. In some rare cases, couples may not produce any healthy embryos. Future gene editing might help these couples have a healthy biological child. For other couples, gene editing could increase the number of healthy embryos available by fixing some that would otherwise be thrown away, Amato says. “If it’s shown to be just as safe and effective as PGD, I’d say, ‘Why not use it?’ ”

Citations

N.M. Gaudelli et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature. Published online October 25, 2017. doi: 10.1038/nature24644.

G. Li et al. Highly efficient and precise base editing in discarded human tripronuclear embryos. Protein & Cell. Vol. 8, October 2017, p. 776. doi:10.1007/s13238-017-0458-7.

P. Liang et al. Correction of β-thalassemia mutant by base editor in human embryos. Protein & Cell. Published online September 23, 2017. doi: 10.1007/s13238-017-0475-6.

N.M.E. Fogarty et al. Genome editing reveals a role for OCT4 in human embryogenesis. Nature. Vol. 550. October 5, 2017, p. 67. doi:10.1038/nature24033.

D. Egli et al. Inter-homologue repair in fertilized human eggs? BioRxiv.org. August 28, 2017. doi: https://doi.org/10.1101/181255

H. Ma et al. Correction of a pathogenic gene mutation in human embryos. Nature. Vol. 548, August 24, 2017, p. 413. doi:10.1038/nature23305.

L. Tang et al. CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein. Molecular Genetics and Genomics. Vol. 292, June 2017, p. 525, Published online March 1, 2017. doi: 10.1007/s00438-017-1299-z.

A. Charo et al. Human genome editing: Science, ethics and governance. Report of the National Academies of Sciences, Engineering and Medicine. February 14, 2017. 

Further Reading

T. H. Saey. New CRISPR gene editors can fix RNA and DNA one typo at a time. Science News Online. October 25, 2017.

T. H. Saey. In a first, human embryos edited to explore gene function. Science News. Vol. 192, October 14, 2017, p. 8.

T. H. Saey. Gene editing of human embryos gets rid of a mutation that causes heart failure. Science News. Vol. 192, September 2, 2017, p. 6.

T. H. Saey. Gene editing of human embryos yields early results. Science News. Vol. 191, April 15, 2017, p. 16.

T. H. Saey. Human gene editing therapies are OK in certain cases, panel advises. Science News. Vol. 191, March 18, 2017, p. 7.

T. H. Saey. Gene in human embryos altered by Chinese researchers. Science News Online. April 23, 2015.

T. H. Saey. Researchers edit genes in human embryos for second time. Science News Online. April 8, 2016.

R. Mestel. CRISPR had a life before it became a gene-editing tool. Science News. Vol. 191, April 15, 2017, p. 22.

Get Science News headlines by e-mail.

More from this issue of Science News

[title_1]
From the Nature Index Paid Content